paclitaxel - Profile

What are the generic drug sources for paclitaxel and what is the scope of patent protection?

Paclitaxel is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Actavis Totowa, Alembic, Dash Pharms, Fresenius Kabi Usa, Gland, Hikma, Hospira, MSN, Pharmobedient, Pliva Lachema, Sandoz, Teva Pharms, Teva Pharms Usa, Hq Spclt Pharma, Bristol-myers, Am Regent, Cipla, Hengrui Pharma, Mylan, Shuangcheng, and Teva Pharms Inc, and is included in twenty-four NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Paclitaxel has one hundred and ninety-seven patent family members in thirty-one countries.

Summary for paclitaxel

International Patents:	197
US Patents:	7
Tradenames:	3
Applicants:	22
NDAs:	24
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for paclitaxel

Paragraph IV (Patent) Challenges for PACLITAXEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABRAXANE	For Injection Suspension	paclitaxel	100 mg/vial	021660	1	2015-12-11

US Patents and Regulatory Information for paclitaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	075436-001	Nov 12, 2004		DISCN	No	No
Accord Hlthcare	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	205720-001	Aug 17, 2018	AP	RX	No	No
Actavis Totowa	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	090130-001	Dec 9, 2009	AP	RX	No	No
Alembic	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874-001	Oct 20, 2022	AP	RX	No	No
Dash Pharms	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	091540-001	Sep 29, 2011		DISCN	No	No
Fresenius Kabi Usa	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	077574-001	Nov 27, 2006	AP	RX	No	No

Expired US Patents for paclitaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005

EU/EMA Drug Approvals for paclitaxel

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Abraxane	paclitaxel	EMEA/H/C/000778Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	no	no	no	2008-01-11
ratiopharm GmbH	Pazenir	paclitaxel	EMEA/H/C/004441Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	yes	no	no	2019-05-06
Inceptua AB	Apealea	paclitaxel	EMEA/H/C/004154Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.	Authorised	no	no	no	2018-11-20
Norton Healthcare Ltd.	Paxene	paclitaxel	EMEA/H/C/000216Paxene is indicated for the treatment of patients with:• advanced AIDS-related Kaposi's sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. Limited efficacy data supports this indication (see section 5.1).	Withdrawn	no	no	no	1999-07-19

International Patents for paclitaxel

Country	Patent Number	Title	Estimated Expiration
Hungary	E049789
Croatia	P20211062
Brazil	112012024442
China	103169729	Methods and compositions for treating proliferative diseases
South Korea	102205710
Poland	2301531

Supplementary Protection Certificates for paclitaxel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1853250	122014000065	Germany		PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
1853250	2014C/037	Belgium		PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230
0961612	SZ 41/2009	Austria		PRODUCT NAME: PACLITAXEL ALBUMIN
0961612	132009901771196	Italy		PRODUCT NAME: PACLITAXEL(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/428/001, 20080114
1853250	300673	Netherlands		PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
1853250	132014902271575	Italy		PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220

Investment Scenario, Market Dynamics, and Financial Trajectory for Paclitaxel

Last updated: February 3, 2026

Executive Summary

Paclitaxel, a chemotherapeutic agent primarily used for treating various cancers such as ovarian, breast, and non-small cell lung cancer, continues to hold significant market relevance despite emerging competition from targeted therapies and biosimilars. The global market for paclitaxel is projected to reach USD 650 million by 2027, driven by increased cancer prevalence, expanding indications, and advances in formulation technologies. Investments in production capacity, biosimilar development, and innovative delivery methods could offer lucrative opportunities, provided regulatory hurdles and patent landscapes are navigated effectively.

---

What Is the Current Market Landscape for Paclitaxel?

Market Size and Revenue Estimates

Year	Estimated Global Market (USD Million)	Compound Annual Growth Rate (CAGR) %
2023	530	4.5%
2025	605	5.0%
2027	650	4.0%

Source: MarketsandMarkets, 2022[1]

The market remains anchored in established formulations, mainly available via brand names like Taxol (Bristol-Myers Squibb) and Paclitaxel (generic). The decline of originator products due to patent expiry has increased the adoption of generics and biosimilars, affecting revenue streams.

Market Drivers

• Rising incidence of cancers worldwide: WHO reports 19.3 million new cancer cases in 2020, expected to grow annually.
• Expanded therapeutic indications: New clinical data supports paclitaxel use in combination therapies.
• Advancements in formulation: Albumin-bound, liposomal, and nanoparticle paclitaxel formulations improve efficacy and reduce side effects.
• Emerging markets: Asian economies and Latin America see increased healthcare investment, augmenting demand.

Market Restraints

Restraint	Description
Patent expirations	Increased generic competition limits margins.
Competition from targeted therapies	Immunotherapies and targeted agents replace paclitaxel in certain indications.
Regulatory challenges	Approval processes for biosimilars and new formulations are rigorous.
Manufacturing complexities	Production involves complex purification processes, impacting scalability and cost.

---

Investment Scenarios in Paclitaxel

1. Opportunities in Biosimilars and Generics

The patent cliff for paclitaxel since 2014 has led to a proliferation of biosimilars. This has created competitive pricing pressures but also new opportunities for manufacturers to expand market share through quality and affordability.

Biosimilar Market Entry Timeline	Potential Revenue Impact	Key Players
2015-2020	USD 100M decrease in average prices	Celltrion, Sandoz, Teva
2021-2023	Increased adoption; price stabilization	Multiple generics entering market

2. Formulation Innovation and Delivery Platforms

Investment in alternative formulations (e.g., nanoparticle albumin-bound paclitaxel, Abraxane) shows promise:

Formulation Type	Advantages	Development Stage	Investment Considerations
Nanoparticle paclitaxel	Reduced toxicity, improved solubility	Marketed (e.g., Abraxane)	High R&D and regulatory costs
Liposomal delivery	Targeted delivery, enhanced efficacy	Preclinical	Technical complexity, regulatory pathways
Oral paclitaxel	Improved patient compliance	Early clinical	Bioavailability challenges

3. Manufacturing and Supply Chain Optimization

With demand stabilizing, companies investing in:

• Single-use bioprocessing technologies
• Advanced purification methods
• Quality control automation

could realize cost advantages and increased margins.

4. Geographic Market Expansion

Emerging markets—India, China, Brazil—offer significant growth potential:

Region	Market Size (USD Million, 2027)	Growth Rate (CAGR %)	Key Opportunities
China	150	6.0%	Infrastructure investments, local manufacturing
India	80	7.5%	Generic penetration, price sensitivity
Brazil	50	4.8%	Expanding healthcare access

Investment Risks

• Patent litigation and biosimilar approval delays
• Stringent regulatory environment in developed markets
• Price erosion due to generic competition
• Disruption from alternative therapies (immuno-oncology)

---

Market Dynamics and Competitive Landscape

Major Players Profile

Company	Market Share (Estimated, 2023)	Products	Strategic Focus
Bristol-Myers Squibb	35%	Taxol (Brand), Abraxane	Innovation, global distribution
Teva	20%	Generic paclitaxel formulations	Cost leadership, biosphere development
Sandoz	15%	Biosimilars	Biosimilar pipeline expansion
Other Players	30%	Various	Regional growth, formulation upgrades

Regulatory and Patent Policy Overview

• The U.S. FDA’s Abbreviated New Drug Application (ANDA) pathway accelerates biosimilar approvals.
• Patent protections generally expire after 12-14 years in major markets, but litigation often extends exclusivity.
• The European Medicines Agency (EMA) permits biosimilar entry after patent expiry, fostering competition.

Pricing Strategies

Strategy	Description	Impact
Cost-plus pricing	Based on manufacturing cost + margin	Maintains margins in commoditized markets
Value-based pricing	Based on clinical benefits	Supports premium pricing for innovative formulations
Penetration pricing	Lower prices to gain market share	Suitable for emerging markets and biosimilars

---

Financial Trajectory and Forecasts

Revenue Projections

Year	Peak Sales Potential (USD Million)	Notes
2023	530	Stable, mature market
2025	605	Biosimilar adoption accelerates
2027	650	Market stabilization with new formulations

Profit Margins and Cost Structures

Cost Element	Approximate Share of Revenue (%)	Notes
Raw materials	15-20%	High requirement for sterile and purified compounds
R&D	8-12%	Major for formulation innovations
Manufacturing	10-15%	Bioprocessing and quality control
Regulatory	2-4%	Approval and compliance costs

Investment Payback Periods

• Biosimilar development: 3-5 years post-investment with a potential ROI of 15-20%
• Formulation innovation: 4-7 years, with high risk but potential premium pricing
• Capacity expansion: 1-3 years, quick returns in growing markets

---

Comparison: Paclitaxel vs. Emerging Alternatives

Parameter	Paclitaxel	Targeted/Immunotherapies	Impact on Market
Efficacy	Proven, established	Variable, often higher	Market stability for traditional chemotherapies
Safety profile	Recognized toxicities	Often better tolerated	Competitive pressure in specific indications
Cost	Lower (especially generics)	Higher	Price competition risk
Regulatory pathway	Well-established	More complex	Market entry times vary

---

Key Investment Considerations

• Patent and Regulatory Landscape: Navigating patent expirations and biosimilar approval pathways is crucial.
• Market Diversification: Expanding into emerging geographies reduces risks associated with mature markets.
• Innovation Focus: Developing novel formulations or delivery platforms can command premium pricing.
• Cost Optimization: Enhancing manufacturing efficiencies sustains margins amid price erosion.
• Competitive Positioning: Differentiation through quality, efficacy, or biosimilar portfolios strengthens market share.

---

Key Takeaways

• Growing Market: The global paclitaxel market is projected to reach USD 650 million by 2027 despite biosimilar competition.
• Patent Cliff Effects: Expiry has led to increased generic penetration, pressuring prices but opening opportunities for biosimilar firms.
• Formulation Innovation: Advanced delivery platforms, including nanoparticle and liposomal variants, present lucrative investment avenues.
• Emerging Markets: Rapidly expanding healthcare infrastructure in Asia and Latin America offer substantial growth potential.
• Regulatory Navigation: Success relies on adept management of approval pipelines, patent strategies, and regional compliance.

---

FAQs

1. What are the main factors driving demand for paclitaxel?
The rising global incidence of cancers, expanded indications, improved formulations, and increased adoption in emerging markets drive demand.

2. How does biosimilar competition impact paclitaxel revenues?
Biosimilars significantly lower prices post-patent expiry, reducing original manufacturer margins but presenting opportunities for biosimilar entrants and cost-based providers.

3. Are new formulations of paclitaxel likely to replace existing products?
Innovative formulations, such as nanoparticle-based paclitaxel (e.g., Abraxane), offer clinical benefits that support their growth alongside traditional versions.

4. What regulatory pathways influence paclitaxel market entry?
In the U.S., ANDA facilitates biosimilar approvals; in Europe, EMA pathways support biosimilar market entry post-patent expiry, with varying regional requirements.

5. What are the risks associated with investing in paclitaxel?
Patent litigation, regulatory delays, price erosion due to generics, and competition from targeted therapies pose significant risks.

---

References

[1] MarketsandMarkets. (2022). Paclitaxel Market by Application, Region - Global Forecast to 2027.